We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tysabri

News List

New subcutaneous formulation of Tysabri approved in UK pharmatimes
April 19, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new subcutaneous (SC) formulation for Biogen’s multiple sclerosis treatment Tysabri.
EU nod for new formulation of Biogen's Tysabri pharmatimes
April 13, 2021
European regulators have approved Biogen's application to market a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn pharmaceutical-technology
March 29, 2017
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn.
Perrigo to sell Tysabri drug royalty to RPI for $2.85bn pharmaceutical-technology
March 02, 2017
Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of ...